Physician profile
Aasef G Shaikh
NPI 1922234152
$185,538.24
in general payments reported to CMS, 2019-2025
24 companies · $20K in 2025
The $20K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $11K · 2021: $14K · 2022: $41K · 2023: $38K · 2024: $392 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Travel and Lodging: $5,721 · Food and Beverage: $1,904 · Consulting Fee: $1,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,016.00 |
| Travel and Lodging | $5,721.25 |
| Food and Beverage | $1,904.15 |
| Consulting Fee | $1,545.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $157,247.24 | 2019-2023 | Inbrija |
| Merz Pharmaceuticals, LLC | $19,237.90 | 2021-2025 | Inbrija, Xeomin |
| Biogen, INC. | $3,185.84 | 2021-2022 | |
| Medtronic, INC. | $2,096.33 | 2021-2022 | |
| Kyowa Kirin, INC. | $1,902.37 | 2019-2023 | Nourianz |
| Abbvie INC. | $374.19 | 2020-2025 | Botox, Duopa |
| Teva Pharmaceuticals USA, INC. | $191.32 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $177.32 | 2022-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $168.39 | 2019-2025 | Crexont, Rytary |
| Abbott Laboratories | $150.53 | 2019-2025 | Infinity |
| Revance Therapeutics, INC. | $120.94 | 2024 | Daxxify |
| Boston Scientific Corporation | $99.75 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $88.83 | 2019-2024 | Ingrezza |
| Avion Pharmaceuticals | $83.74 | 2022-2023 | Dhivy |
| Astrazeneca Pharmaceuticals Lp | $81.23 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $79.99 | 2022 | |
| Medtronic USA, INC. | $63.69 | 2019 | |
| Ascendis Pharma Endocrinology INC | $55.00 | 2025 | Yorvipath |
| Mdd US Operations, LLC | $44.74 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $22.93 | 2023 | Nuedexta |
| Allergan, INC. | $19.81 | 2019 | |
| Mirum Pharmaceuticals, INC. | $17.09 | 2024 | Cholbam |
| Adamas Pharmaceuticals, INC. | $15.07 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aasef Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.